July 13, 2015Virology JournalOpen Access

In vitro characterisation of a pleconaril/pirodavir-like compound with potent activity against rhinoviruses

View Full Paper

Ask AI

Bookmark

Population

In vitro panel of rhino- and enteroviruses

Design

Preclinical

Authors

Discussion

ca603 shows in vitro rhinovirus activity; leaves open translation to clinical benefit in asthma or COPD exacerbations.

Population

In vitro panel of rhino- and enteroviruses

Intervention

ca603 (an analogue of pirodavir with a modified linker structure)

Outcome

Antiviral activity and mechanism of action (capsid binding)surrogate

ca603 is a novel capsid-binding molecule that inhibits rhinovirus replication by interacting with the VP1 protein.

Lacroix et al. (2015) studied this question.

View Full Paper

Ask AI

Bookmark